Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis

Stefano Perlini, Francesco Salinaro, Francesco Musca, Roberta Mussinelli, Michele Boldrini, Ambra Raimondi, Paolo Milani, Andrea Foli, Francesco Cappelli, Federico Perfetto, Giovanni Palladini, Claudio Rapezzi, Giampaolo Merlini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P

Original languageEnglish
Pages (from-to)1121-1131
Number of pages11
JournalJournal of Hypertension
Volume32
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Amyloidosis
Light
Heart Failure
Diastolic Heart Failure
Hypertrophy
Heart Diseases
Pressure

Keywords

  • amyloidosis
  • midwall fractional shortening
  • prognosis
  • systolic function

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. / Perlini, Stefano; Salinaro, Francesco; Musca, Francesco; Mussinelli, Roberta; Boldrini, Michele; Raimondi, Ambra; Milani, Paolo; Foli, Andrea; Cappelli, Francesco; Perfetto, Federico; Palladini, Giovanni; Rapezzi, Claudio; Merlini, Giampaolo.

In: Journal of Hypertension, Vol. 32, No. 5, 2014, p. 1121-1131.

Research output: Contribution to journalArticle

Perlini, S, Salinaro, F, Musca, F, Mussinelli, R, Boldrini, M, Raimondi, A, Milani, P, Foli, A, Cappelli, F, Perfetto, F, Palladini, G, Rapezzi, C & Merlini, G 2014, 'Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis', Journal of Hypertension, vol. 32, no. 5, pp. 1121-1131. https://doi.org/10.1097/HJH.0000000000000120
Perlini, Stefano ; Salinaro, Francesco ; Musca, Francesco ; Mussinelli, Roberta ; Boldrini, Michele ; Raimondi, Ambra ; Milani, Paolo ; Foli, Andrea ; Cappelli, Francesco ; Perfetto, Federico ; Palladini, Giovanni ; Rapezzi, Claudio ; Merlini, Giampaolo. / Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. In: Journal of Hypertension. 2014 ; Vol. 32, No. 5. pp. 1121-1131.
@article{07e422be8cd24f9ba78b40953467c7a7,
title = "Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis",
abstract = "BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P",
keywords = "amyloidosis, midwall fractional shortening, prognosis, systolic function",
author = "Stefano Perlini and Francesco Salinaro and Francesco Musca and Roberta Mussinelli and Michele Boldrini and Ambra Raimondi and Paolo Milani and Andrea Foli and Francesco Cappelli and Federico Perfetto and Giovanni Palladini and Claudio Rapezzi and Giampaolo Merlini",
year = "2014",
doi = "10.1097/HJH.0000000000000120",
language = "English",
volume = "32",
pages = "1121--1131",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis

AU - Perlini, Stefano

AU - Salinaro, Francesco

AU - Musca, Francesco

AU - Mussinelli, Roberta

AU - Boldrini, Michele

AU - Raimondi, Ambra

AU - Milani, Paolo

AU - Foli, Andrea

AU - Cappelli, Francesco

AU - Perfetto, Federico

AU - Palladini, Giovanni

AU - Rapezzi, Claudio

AU - Merlini, Giampaolo

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P

AB - BACKGROUND: Cardiac amyloidosis represents an archetypal form of restrictive heart disease, characterized by profound diastolic dysfunction. As ejection fraction is preserved until the late stage of the disease, the majority of patients do fulfill the definition of diastolic heart failure, that is, heart failure with preserved ejection fraction (HFpEF). In another clinical model of HFpEF, that is, pressure-overload hypertrophy, depressed midwall fractional shortening (mFS) has been shown to be a powerful prognostic factor. OBJECTIVE AND METHODS: To assess the potential prognostic role of mFS in cardiac light-chain amyloidosis with preserved ejection fraction, we enrolled 221 consecutive untreated patients, in whom a first diagnosis of cardiac light-chain amyloidosis was concluded between 2008 and 2010. HFpEF was present in 181 patients. Patients in whom cardiac involvement was excluded served as controls (n=121). Prognosis was assessed after a median follow-up of 561 days. RESULTS: When compared with light-chain amyloidosis patients without myocardial involvement, cardiac light-chain amyloidosis was characterized by increased wall thickness (P

KW - amyloidosis

KW - midwall fractional shortening

KW - prognosis

KW - systolic function

UR - http://www.scopus.com/inward/record.url?scp=84898406800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898406800&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000000120

DO - 10.1097/HJH.0000000000000120

M3 - Article

C2 - 24509117

AN - SCOPUS:84898406800

VL - 32

SP - 1121

EP - 1131

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -